155 related articles for article (PubMed ID: 36567009)
1. 1,25(OH)
Erzurumlu Y; Aydogdu E; Dogan HK; Catakli D; Muhammed MT; Buyuksandic B
Cell Signal; 2023 Mar; 103():110577. PubMed ID: 36567009
[TBL] [Abstract][Full Text] [Related]
2. Progesterone regulates the endoplasmic reticulum-associated degradation and Unfolded Protein Response axis by mimicking the androgenic stimulation in prostate cancer cells.
Erzurumlu Y; Dogan HK; Catakli D
Mol Biol Rep; 2023 Feb; 50(2):1253-1265. PubMed ID: 36445513
[TBL] [Abstract][Full Text] [Related]
3. Triiodothyronine positively regulates endoplasmic reticulum-associated degradation (ERAD) and promotes androgenic signaling in androgen-dependent prostate cancer cells.
Erzurumlu Y; Muhammed MT
Cell Signal; 2023 Sep; 109():110745. PubMed ID: 37271348
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. Estrogens drive the endoplasmic reticulum-associated degradation and promote proto-oncogene c-Myc expression in prostate cancer cells by androgen receptor/estrogen receptor signaling.
Erzurumlu Y; Dogan HK; Catakli D; Aydogdu E; Muhammed MT
J Cell Commun Signal; 2023 Sep; 17(3):793-811. PubMed ID: 36696010
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
7. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
10. Modulation of vitamin D receptor and estrogen receptor by 1,25(OH)2-vitamin D3 in T-47D human breast cancer cells.
Davoodi F; Brenner RV; Evans SR; Schumaker LM; Shabahang M; Nauta RJ; Buras RR
J Steroid Biochem Mol Biol; 1995 Aug; 54(3-4):147-53. PubMed ID: 7662588
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.
Hedlund TE; Moffatt KA; Miller GJ
J Steroid Biochem Mol Biol; 1996 Jun; 58(3):277-88. PubMed ID: 8836163
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
Yang ES; Maiorino CA; Roos BA; Knight SR; Burnstein KL
Mol Cell Endocrinol; 2002 Jan; 186(1):69-79. PubMed ID: 11850123
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.
Mooso B; Madhav A; Johnson S; Roy M; Moore ME; Moy C; Loredo GA; Mehta RG; Vaughan AT; Ghosh PM
Genes Cancer; 2010 Nov; 1(9):927-940. PubMed ID: 21552398
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone-stimulated glucocorticoid receptor signaling positively regulates the endoplasmic reticulum-associated degradation (ERAD) mechanism in hepatocellular carcinoma cells.
Erzurumlu Y; Dogan HK; Cataklı D
Steroids; 2023 Jul; 195():109238. PubMed ID: 37044236
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of endoplasmic reticulum stress and oxidative stress by vitamin D in endothelial cells.
Haas MJ; Jafri M; Wehmeier KR; Onstead-Haas LM; Mooradian AD
Free Radic Biol Med; 2016 Oct; 99():1-10. PubMed ID: 27458123
[TBL] [Abstract][Full Text] [Related]
17. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
[TBL] [Abstract][Full Text] [Related]
18. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
19. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.
Giangreco AA; Dambal S; Wagner D; Van der Kwast T; Vieth R; Prins GS; Nonn L
J Steroid Biochem Mol Biol; 2015 Apr; 148():156-65. PubMed ID: 25305352
[TBL] [Abstract][Full Text] [Related]
20. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
